Screening Theory and Study Design: The Basics

Cancer Screening: Theory and Practice

Volumn , Issue , 2021, Pages 29-53

  Prorok, Philip C ^a   Kramer, Barnett S ^a,b   Gohagan, John K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85130927994     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780429179587-5     Document Type: Chapter

References (77)

1. Physicians Data Query. Cancer screening. Bethesda, MD: National Cancer Institute, 1997.
2. Sackett DL, Holland WW. Controversy in the detection of disease. Lancet 1975; 23:357-359.
3. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public Health Paper No. 34. Geneva: World Health Organization, 1968.
4. Summary and general recommendations. In: Miller AB, ed. Screening in Cancer. UICC Technical Report Series, Vol. 40. Geneva: International Union Against Cancer, 1978: 334-338.
5. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64:1263-1272.
6. Thorner RM, Remein QR. Principles and procedures in the evaluation of screening for disease. Public Health Monograph No. 67. Washington, DC: U.S. Public Health Service, 1961.
7. Morrison AS. Screening in Chronic Disease. New York: Oxford University Press, 1985.
8. Day NE. The theoretical basis for cancer screening. In: Miller AB, ed. Advances in Cancer Screening. Boston: Kluwer Academic Publishers, 1996:9-24.
9. Prorok PC. Evaluation of screening programs for the early detection of cancer. In: Cornell RG, ed. Statistical Methods for Cancer Studies. New York: Marcel Dekker, 1984:267-328.
10. Prorok PC, Connor RJ. Screening for the early detection of cancer. Cancer Investigation 1986; 4:225-238.
11. Sackett DL. Periodic examination of patients at risk. In: Schottenfeld D, ed. Cancer Epidemiology and Prevention, Current Concepts. Springfield, IL: Charles C. Thomas 1975:437-454.
12. Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika 1969; 56:601-614.
13. Hutchison GB, Shapiro S. Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 1968; 41:665-681.
14. Albert A, Gertman PM, Louis T. Screening for the early detection of cancer-I: the temporal natural history of a progressive disease state. Math Biosci 1978; 40: 1-59.
15. Zelen M. Theory of early detection of breast cancer in the general population. In: Heuson JC, Mattheiem WH, Rozenzweig M, eds. Breast Cancer: Trends in Research and Treatment. New York: Raven Press, 1976:287-300.
16. Bailar JC. Mammography: a contrary view. Ann Intern Med 1976; 84:77-84.
17. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914-923.
18. Bessho F. Effects of mass screening on age-specific incidence of neuroblastoma. Int J Cancer 1996; 67:520-522.
19. Kramer BS, Gohagan JK, Prorok PC. Is screening for prostate cancer the current gold standard?-“No.” Euro J Cancer 1997; 33:348-353.
20. Morrison AS. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol 1982; 11: 261-267.
21. Aron JL, Prorok PC. An analysis of the mortality effect in a breast cancer screening study. Int J Epidemiol 1986; 15:36-43.
22. Chamberlain J. Planning of screening programs for evaluation and non-randomized approaches to evaluation. In: Prorok PC, Miller AB, eds. Screening for Cancer. I-General Principles on Evaluation of Screening for Cancer and Screening for Lung, Bladder and Oral Cancer. UICC Technical Report Series, Volume 78. Geneva: International Union Against Cancer, 1984:5-17.
23. Tabar L, Fagerberg CJG, Gad A, Baldetorp L, Holmberg LH, Grontoft O, Ljung-quist U, Lundstrom B, Manson JC, Eklund G, Day NE, Pettersson F. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985; i:829-832.
24. Roberts MM, Alexander FE, Anderson TJ, Chetty U, Donnan PT, Forrest P, Hepburn W, Huggins A, Kirkpatrick AE, Lamb J, Muir BR, Prescott RJ. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 1990; 335: 241-246.
25. Day NE, Williams DRR, Khaw KT. Breast cancer screening programs: the development of a monitoring and evaluation system. Br J Cancer 1989; 59:954-958.
26. Paci E, Ciatto S, Buiatti E, Cecchini S, Palli D, Rosselli del Turco M. Early indicators of efficacy of breast cancer screening programs. Results of the Florence district program. Int J Cancer 1990; 46:198-202.
27. Morrison AS. Case definition in case-control studies of the efficacy of screening. Am J Epidemiol 1982; 115:6-8.
28. Sasco AJ, Day NE, Walter SD. Case-control studies for the evaluation of screening. J Chron Dis 1986; 39:399-405.
29. Weiss NS. Control definition in case-control studies of the efficacy of screening and diagnostic testing. Am J Epidemiol 1983; 118:457-460.
30. Connor RJ, Prorok PC, Weed DL. The case-control design and the assessment of the efficacy of cancer screening. J Clin Epidemiol 1991; 44:1215-1221.
31. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH. Randomized clinical trials: perspectives on some recent ideas. N Engl J Med 1976; 295:74-80.
32. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Selection, follow-up, and analysis in the Health Insurance Plan study: a randomized trial with breast cancer screening. Natl Cancer Inst Monogr 1985; 67:65-74.
33. Bearhs OH, Shapiro S, Smart C. Report of the working group to review the National Cancer Institute/American Cancer Society breast cancer detection demonstration projects. J Natl Cancer Inst 1979; 62:639-709.
34. Hakama M, Miller AB, Day NE. Screening for Cancer of the Uterine Cervix. IARC Scientific Publications No. 76. Lyon: International Agency for Research on Cancer, 1986.
35. Ebeling K, Nischan P. Screening for lung cancer-results from a case-control study. Int J Cancer 1987; 40:141-144.
36. Friedman GD, Hiatt RA, Quesenberry CP, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991; 337:1526-1529.
37. Oshima A, Hirata N, Ubukata T, Urneda K, Fujimato I. Evaluation of a mass screening program for stomach cancer with a case-control design. Int J Cancer 1986; 38:829-833.
38. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326:653-657.
39. Sobue T, Suzuki T, Naruke T, The Japanese Lung Cancer Screening Research Group. A case-control study for evaluating lung cancer screening in Japan. Int J Cancer 1992; 50:230-237.
40. Benino F, Gatta G, D’Alto M, Crosignani P, Riboli E. Use of case-control studies in evaluation of screening programmes. In: Prorok PC, Miller AB, eds. Screening for Cancer I-General Principles on Evaluation of Screening for Cancer and Screening for Lung, Bladder and Oral Cancer. UICC Technical Report Series, Volume 78. Geneva: International Union Against Cancer, 1984: 29-43.
41. Dubin N, Friedman DR, Toniola PG, Pasternack BS. Breast cancer detection centers and case-control studies of the efficacy of screening. J Chron Dis 1987; 40:1041-1050.
42. Hosek RS, Flanders WD, Sasco AJ. Bias in case-control studies of screening effectiveness. Am J Epidemiol 1996; 143:193-201.
43. Moss SM. Case-control studies of screening. Int J Cancer 1991; 20:1-6.
44. Weiss NS, McKnight B, Stevens NG. Approaches to the analysis of case-control studies of the efficacy of screening for cancer. Am J Epidemiol 1992; 135:817-823.
45. Friedman DR, Dubin N. Case-control evaluation of breast cancer screening efficacy. Am J Epidemiol 1991; 33:974-984.
46. Janzon L, Andersson I. The Malmo mammographic screening trial. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge: Cambridge University Press, 1991:37-44.
47. Eddy DM. Screening for Cancer-Theory, Analysis and Design. Englewood Cliffs, NJ: Prentice-Hall, 1980.
48. Habbema JDF, Lubbe JTN, Van der Maas PJ, VanOortmarssen GJ. A computer simulation approach to the evaluation of mass screening. In: Van Bemmel JH, Ball MJ, Wigertz O, eds. MEDINFO 83. Amsterdam: North-Holland, 1983:1222-1225.
49. Kirch RLA, Klein M. Surveillance schedules for medical examinations. Management Science 1974; 20:1403-1409.
50. Knox EG A simulation system for screening procedures. In: McLachlan G, ed. The Future and Present Indicatives, Problems and Progress in Medical Care. Ninth Series, Nuffield Provincial Hospitals Trust. London: Oxford University Press, 1973: 17-55.
51. Shapiro S, Venet W, Strax P, Venet L. Periodic Screening for Breast Cancer. The Health Insurance Plan Project and Its Sequelae, 1963-1986. Baltimore: The Johns Hopkins University Press, 1988.
52. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiologic Clinics of North America 1992; 30: 187-210.
53. Shiue WK, Bain LJ. Experiment size and power comparisons for two-sample Poisson tests. Appi Statist 1982; 31:130-134.
54. Taylor WF, Fontana RS. Biometrie design of the Mayo lung project for early detection and localization of bronchogenic carcinoma. Cancer 1972; 30:1344-1347.
55. Moss S, Draper GJ, Hardcastle JD, Chamberlain J. Calculation of sample size in trials of screening for early diagnosis of disease. Int J Epidemiol 1987; 16:104-110.
56. Prorok PC. Screening studies. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer Prevention and Control. New York: Marcel Dekker, 1995:225-242.
57. Freedman LS, Green SB. Statistical designs for investigating several interventions in the same study: methods for cancer prevention trials. J Natl Cancer Inst 1990; 82:910-914.
58. Miller AB, Howe GR, Wall C. The national study of breast cancer screening. Clin Invest Med 1981; 4:227-258.
59. Gilbertsen VA, Church TR, Grewe FA, Mandel JS, McHugh RM, Schuman LM, Williams SE. The design of a study to assess occult-blood screening for colon cancer. J Chron Dis 1980; 33:107-114.
60. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute. Urol 1994; 152:1905-1909.
61. Etzioni RD, Connor RJ, Prorok PC, Self SG. Design and analysis of cancer screening trials. Statistical Methods in Medical Research 1995; 4:3-17.
62. Fontana RS. Screening for lung cancer: recent experience in the United States. In: Hansen HH, ed. Lung Cancer: Basic and Clinical Aspects. Boston: Martinus Nijhoff Publishers, 1986:91-111.
63. Frisell J, Eklund G, Hellstrom L, Glas U, Somell A. The Stockholm Breast Cancer Screening Trial-5-year results and stage at discovery. Breast Cancer Research and Treatment 1989; 13:79-87.
64. Moss S. Personal communication, 1994.
65. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten-to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69:349-355.
66. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 1988; 80:1125-1132.
67. Connor RJ, Prorok PC. Issues in the mortality analysis of randomized controlled trials of cancer screening. Controlled Clinical Trials 1994; 5:81-99.
68. Etzioni R, Self SG. On the catch-up time method for analyzing cancer screening trials. Biometrics 1995; 51:31-43.
69. Zucker DM, Lakatos E. Weighted logrank-type statistics for comparing survival curves when there is a time lag in the effectiveness of treatment. Biometrika 1990; 77:853-864.
70. Self SG An adaptive weighted logrank test with application to cancer prevention and screening trials. Biometrics 1991; 47:975-986.
71. Self SG, Etzioni R. A likelihood ratio test for cancer screening trials. Biometrics 1995; 51:44-50.
72. Walter SD, Stitt LW. Evaluating the survival of cancer cases detected by screening. Statistics in Medicine 1987; 6:885-900.
73. Xu JL, Prorok PC. Non-parametric estimation of the post-lead time survival distribution of screen detected cancer cases. Statistics in Medicine 1995; 14:2715-2725.
74. Shapiro S, Goldberg JD, Hutchison GB. Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol 1974; 100:357-366.
75. Kafadar K, Prorok PC. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials. Statistics in Medicine 1994; 13:569-586.
76. Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983; 118:865-886.
77. Connor RJ, Chu KC, Smart CR. Stage-shift cancer screening model. J Clin Epidemiol 1989; 42:1083-1095.